Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent

These results would suggest that chemoprevention trials in ovarian cancer will be eagerly embraced by this patient population. (Study supported by NIH 5P50CA83591.)